CureVac’s Covid-19 Vaccine Disappoints in Clinical Trial
The New York Times
A preliminary analysis showed that CureVac’s mRNA vaccine had an efficacy of just 47 percent. “This is pretty devastating for them,” one expert said.
The German company CureVac delivered disappointing preliminary results on Wednesday from a clinical trial of its Covid-19 vaccine, dimming hopes that it could help fill the world’s great need. The trial, which included 40,000 volunteers in Latin America and Europe, estimated that CureVac’s mRNA vaccine had an efficacy of just 47 percent, among the lowest reported so far from any Covid-19 vaccine maker. The trial will continue as researchers monitor volunteers for new cases of Covid-19, with a final analysis expected in two to three weeks. “We’re going to full speed for the final readout,” Franz-Werner Haas, CureVac’s chief executive, said in an interview. “We are still planning for filing for approval.”
Some women are stocking up on the medications, saying they are concerned that the new administration could take steps to restrict access.
As the glaciers of South America retreat, the supply of freshwater is dwindling and its quality is getting worse.
It’s something turkey often isn’t — undeniably juicy and a guaranteed crowd-pleaser.
A rise in the disease in younger people was not followed by an increase in deaths, a study found, and might be a sign of overdiagnosis.
The Homotherium cub was preserved in Siberian permafrost with its dark fur and flesh intact.
A small study found ChatGPT outdid human physicians when assessing medical case histories, even when those doctors were using a chatbot.
For a century, exoplanet hunters have “discovered” planets around a nearby star, only to retract the claims. But the latest find is for real.
The unidentified patient had recently returned from Africa, where the virus has caused a deadly epidemic, health officials said.
The event produces some of the year’s fastest meteors, although the nearly full moon may make them challenging to spot.
Mr. Musk dug into his companies’ budgets, preferring to cut too much rather than too little and to deal with the fallout later. Under Donald Trump, he is set to apply those tactics to the U.S. government.
Behind the scenes at a Chicago zoo, chimpanzees who spent years entertaining humans are learning to befriend their own kind.